President & Chief Executive Officer
Panna Sharma is the Chief Executive Officer and president of Lantern Pharma. As Chief Executive Officer, Panna oversees Lantern’s use of AI and genomics in developing its therapy product pipeline to innovate the repurposing, revitalization and development of precision therapeutics in oncology.
Prior to joining Lantern in 2018, Panna was the President and Chief Executive Officer of Cancer Genetics, Inc., a provider of DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. In 2001, Panna founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create shareholder value for companies and investors in the life sciences, biotechnology and environmental sciences sectors. Prior to TSG, Mr. Sharma served in the roles of Senior Vice President of E-Business Solutions and Chief Strategy Officer at iXL Inc. (later merged with Scient). For the six years prior to his being at iXL Inc., Mr. Sharma helped successfully found, manage and sell or take public two other consulting and professional services firms. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc. Prior to that, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation.
Panna holds a Bachelor of Science in the Philosophy of Science, Neural Networks and Artificial Intelligence from Boston University.